Millennium Initiates New Clinical Program For Ulcerative Colitis Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Program includes Phase II dose-ranging study and Phase I study in healthy volunteers.
You may also be interested in...
Millennium/Takeda's Phase III IBD Drug Promises Improved Safety
Millennium Pharmaceuticals has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease, the Takeda subsidiary announced Jan. 2
Millennium/Takeda's Phase III IBD Drug Promises Improved Safety
Millennium Pharmaceuticals has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease, the Takeda subsidiary announced Jan. 2
Takeda/Millennium’s Phase III IBD Drug Promises Improved Safety
Millennium Pharmaceuticals, which in this case could call itself "The Takeda Gastroenterology Company," announced Jan. 22 that it has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease